Trial Profile

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tebentafusp (Primary) ; Dexamethasone; Diphenhydramine; Paracetamol
Indications Malignant melanoma; Skin cancer
Focus Registrational; Therapeutic Use
Acronyms TEBE-AM
Sponsors Immunocore

09 Jan 2026 According to an Immunocore media release, data redout from this study is expected in 2H 2026.
07 May 2025 According to an Immunocore media release, company is on track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026.
10 Jan 2025 According to an Immunocore media release, potential data readouts expected in 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com